Cargando…
The renal blood flow reserve in healthy humans and patients with atherosclerotic renovascular disease measured by positron emission tomography using [(15)O]H(2)O
BACKGROUND: Microvascular function plays an important role in ARVD (atherosclerotic renovascular disease). RFR (renal flow reserve), the capacity of renal vasculature to dilate, is known to reflect renal microvascular function. In this pilot study, we assessed PET (positron emission tomography)-base...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995766/ https://www.ncbi.nlm.nih.gov/pubmed/29892792 http://dx.doi.org/10.1186/s13550-018-0395-3 |
_version_ | 1783330666613571584 |
---|---|
author | Päivärinta, Johanna Koivuviita, Niina Oikonen, Vesa Iida, Hidehiro Liukko, Kaisa Manner, Ilkka Löyttyniemi, Eliisa Nuutila, Pirjo Metsärinne, Kaj |
author_facet | Päivärinta, Johanna Koivuviita, Niina Oikonen, Vesa Iida, Hidehiro Liukko, Kaisa Manner, Ilkka Löyttyniemi, Eliisa Nuutila, Pirjo Metsärinne, Kaj |
author_sort | Päivärinta, Johanna |
collection | PubMed |
description | BACKGROUND: Microvascular function plays an important role in ARVD (atherosclerotic renovascular disease). RFR (renal flow reserve), the capacity of renal vasculature to dilate, is known to reflect renal microvascular function. In this pilot study, we assessed PET (positron emission tomography)-based RFR values of healthy persons and renal artery stenosis patients. Seventeen patients with ARVD and eight healthy subjects were included in the study. Intravenous enalapril 1 mg was used as a vasodilatant, and the maximum response (blood pressure and RFR) to it was measured at 40 min. Renal perfusion was measured by means of oxygen-15-labeled water PET. RFR was calculated as a difference of stress flow and basal flow and was expressed as percent [(stress blood flow − basal blood flow)/basal blood flow] × 100%. RESULTS: RFR of the healthy was 22%. RFR of the stenosed kidneys of bilateral stenosis patients (27%) was higher than that of the stenosed kidneys of unilateral stenosis patients (15%). RFR of the contralateral kidneys of unilateral stenosis patients was 21%. There was no difference of statistical significance between RFR values of ARVD subgroups or between ARVD subgroups and the healthy. In the stenosed kidneys of unilateral ARVD patients, stenosis grade of the renal artery correlated negatively with basal (p = 0.04) and stress flow (p = 0.02). Dispersion of RFR values was high. CONCLUSIONS: This study is the first to report [(15)O]H(2)O PET-based RFR values of healthy subjects and ARVD patients in humans. The difference between RFR values of ARVD patients and the healthy did not reach statistical significance perhaps because of high dispersion of RFR values. [(15)O]H(2)O PET is a valuable non-invasive and quantitative method to evaluate renal blood flow though high dispersion makes imaging challenging. Larger studies are needed to get more information about [(15)O]H(2)O PET method in evaluation of renal blood flow. |
format | Online Article Text |
id | pubmed-5995766 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-59957662018-06-26 The renal blood flow reserve in healthy humans and patients with atherosclerotic renovascular disease measured by positron emission tomography using [(15)O]H(2)O Päivärinta, Johanna Koivuviita, Niina Oikonen, Vesa Iida, Hidehiro Liukko, Kaisa Manner, Ilkka Löyttyniemi, Eliisa Nuutila, Pirjo Metsärinne, Kaj EJNMMI Res Original Research BACKGROUND: Microvascular function plays an important role in ARVD (atherosclerotic renovascular disease). RFR (renal flow reserve), the capacity of renal vasculature to dilate, is known to reflect renal microvascular function. In this pilot study, we assessed PET (positron emission tomography)-based RFR values of healthy persons and renal artery stenosis patients. Seventeen patients with ARVD and eight healthy subjects were included in the study. Intravenous enalapril 1 mg was used as a vasodilatant, and the maximum response (blood pressure and RFR) to it was measured at 40 min. Renal perfusion was measured by means of oxygen-15-labeled water PET. RFR was calculated as a difference of stress flow and basal flow and was expressed as percent [(stress blood flow − basal blood flow)/basal blood flow] × 100%. RESULTS: RFR of the healthy was 22%. RFR of the stenosed kidneys of bilateral stenosis patients (27%) was higher than that of the stenosed kidneys of unilateral stenosis patients (15%). RFR of the contralateral kidneys of unilateral stenosis patients was 21%. There was no difference of statistical significance between RFR values of ARVD subgroups or between ARVD subgroups and the healthy. In the stenosed kidneys of unilateral ARVD patients, stenosis grade of the renal artery correlated negatively with basal (p = 0.04) and stress flow (p = 0.02). Dispersion of RFR values was high. CONCLUSIONS: This study is the first to report [(15)O]H(2)O PET-based RFR values of healthy subjects and ARVD patients in humans. The difference between RFR values of ARVD patients and the healthy did not reach statistical significance perhaps because of high dispersion of RFR values. [(15)O]H(2)O PET is a valuable non-invasive and quantitative method to evaluate renal blood flow though high dispersion makes imaging challenging. Larger studies are needed to get more information about [(15)O]H(2)O PET method in evaluation of renal blood flow. Springer Berlin Heidelberg 2018-06-11 /pmc/articles/PMC5995766/ /pubmed/29892792 http://dx.doi.org/10.1186/s13550-018-0395-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Päivärinta, Johanna Koivuviita, Niina Oikonen, Vesa Iida, Hidehiro Liukko, Kaisa Manner, Ilkka Löyttyniemi, Eliisa Nuutila, Pirjo Metsärinne, Kaj The renal blood flow reserve in healthy humans and patients with atherosclerotic renovascular disease measured by positron emission tomography using [(15)O]H(2)O |
title | The renal blood flow reserve in healthy humans and patients with atherosclerotic renovascular disease measured by positron emission tomography using [(15)O]H(2)O |
title_full | The renal blood flow reserve in healthy humans and patients with atherosclerotic renovascular disease measured by positron emission tomography using [(15)O]H(2)O |
title_fullStr | The renal blood flow reserve in healthy humans and patients with atherosclerotic renovascular disease measured by positron emission tomography using [(15)O]H(2)O |
title_full_unstemmed | The renal blood flow reserve in healthy humans and patients with atherosclerotic renovascular disease measured by positron emission tomography using [(15)O]H(2)O |
title_short | The renal blood flow reserve in healthy humans and patients with atherosclerotic renovascular disease measured by positron emission tomography using [(15)O]H(2)O |
title_sort | renal blood flow reserve in healthy humans and patients with atherosclerotic renovascular disease measured by positron emission tomography using [(15)o]h(2)o |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995766/ https://www.ncbi.nlm.nih.gov/pubmed/29892792 http://dx.doi.org/10.1186/s13550-018-0395-3 |
work_keys_str_mv | AT paivarintajohanna therenalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT koivuviitaniina therenalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT oikonenvesa therenalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT iidahidehiro therenalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT liukkokaisa therenalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT mannerilkka therenalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT loyttyniemieliisa therenalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT nuutilapirjo therenalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT metsarinnekaj therenalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT paivarintajohanna renalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT koivuviitaniina renalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT oikonenvesa renalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT iidahidehiro renalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT liukkokaisa renalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT mannerilkka renalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT loyttyniemieliisa renalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT nuutilapirjo renalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o AT metsarinnekaj renalbloodflowreserveinhealthyhumansandpatientswithatheroscleroticrenovasculardiseasemeasuredbypositronemissiontomographyusing15oh2o |